• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.95 -1.57 (-7.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,030,127
Open 20.54
Bid (Size) 18.84 (100)
Ask (Size) 19.25 (2,000)
Prev. Close 20.52
Today's Range 18.68 - 20.54
52wk Range 10.41 - 25.32
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Today 16:50 EDT
Your hard-earned money would be better spent elsewhere. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire

Performance

YTD
-11.1%
-11.1%
1 Month
+25.4%
+25.4%
3 Month
-10.5%
-10.5%
6 Month
-20.5%
-20.5%
1 Year
-0.6%
-0.6%

More News

Read More
News headline image
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
June 30, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via Investor Brand Network
Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗
May 06, 2026
Via Chartmill
Topics Earnings
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
June 01, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
My Top 3 Biotech Stocks for May 2026 ↗
May 20, 2026
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta (SRPT) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
May 06, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
April 22, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
April 20, 2026
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
Via Investor Brand Network
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
March 31, 2026
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
March 26, 2026
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
March 26, 2026
Via MarketMinute
News headline image
The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine
March 26, 2026
Via Finterra
Topics Retirement
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
March 25, 2026
Via Chartmill
Wednesday's session: top gainers and losers ↗
March 25, 2026
Via Chartmill
Which stocks are gapping on Wednesday? ↗
March 25, 2026
Via Chartmill

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 18.95
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 07/10/26 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.77B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap